Compare Quest Diagnostics Inc (DGX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Trip.com Group Ltd — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Trip.com Group Ltd trades at $45.03 (market cap $29.10B). The key difference: Quest Diagnostics Inc and Trip.com Group Ltd are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | TCOM | |
|---|---|---|
Market Cap | $26.21B | $29.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $78.96 |
52-Week Low | $173.49 | $39.84 |
Enterprise Value | $31.97B | $21.75B |
Dividend Yield | 1.45% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Trip.com (TCOM) trades at $45.62, down 3.19% amid bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $62.41B revenue and 53.34% net margin, though recent quarters show mixed earnings performance. Regulatory headwinds persist with a $770M antitrust penalty from China's market regulator in July 2026, while analyst consensus remains bullish with a $59.29 price target.
The stock faces near-term pressure from regulatory scrutiny and technical weakness, but attractive valuations (P/E 6.89) and dominant market position offer long-term upside if execution improves. Key risks include China's regulatory environment and competitive pressures, while institutional ownership shifts indicate cautious sentiment despite Wall Street's buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
